Preliminary data show a numerical advantage in Progression Free Survival in ONCOS-102 treated patients Robust immune activation in the experimental group, with a positive association between immune response and clinical outcome Combination treatment with ONCOS-102 and chemotherapy is well ... read more

Paris, France, January 21, 2020, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reporte... read more

Uppsala, Sweden – January 20, 2020 – As previously communicated Orexo will announce the Full Year Report 2019, incl. Q4, on Thursday, January 30 at  8.00 am CET. The same day at 2.00 pm CET, analysts, investors and media are invited to attend an audiocast with a web presentation where Nikol... read more

Hamilton, ON & Boston, MA – January 13, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan Investment Board (CPPIB). CPPIB ... read more

Hamilton, ON & Boston, MA – January 10, 2020 – Fusion Pharmaceuticals Inc., a privately-held, clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced that Chief Executive Officer John Valliant, Ph.D., will present an overview of the Company... read more